YM543

Astellas Pharma Inc · Phase 2 active Small molecule

At a glance

Generic name	YM543
Sponsor	Astellas Pharma Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YM543 CI brief — competitive landscape report
YM543 updates RSS · CI watch RSS
Astellas Pharma Inc portfolio CI